News | Latest Breaking News Stories & Headlines

Roche to acquire liver drug developer 89bio for €2.4bn

Roche has agreed to buy US biotech firm 89bio for up to $3.5 billion to strengthen its development pipeline of liver and cardiometabolic disease treatments, the Swiss drugmaker said today.

Business • 18 Sep

Roche Ireland's clean up bill for Clare site hits €150.5m

The clean-up bill for Swiss pharma giant Roche's former Co Clare manufacturing site now totals €150.5m in what the company describes as "one of the largest remediation projects of its type in Europe".

Business • 13 Aug

Roche to investigate whether drug can prevent Alzheimer's

Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, as a part of the company's growing development programmefor the disease.

Business • 28 Jul

Roche said its US investment would create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities

Roche to invest $50 billion in US to avoid Trump tariffs

Roche said today it would invest $50 billion in the US over the next five years, creating more than 12,000 new jobs, in the latest massive investment by companies reacting to President Donald Trump's tariffs policy.

Business • 22 Apr

Pre-tax profits at Roche Products (Ireland) grow by 17% in 2023

Revenues at Irish arm of pharma giant Roche rise by 7%

The directors of the Irish arm of pharma giant Roche have stated that there is a need to reduce the lengthy timelines to medicine reimbursement to improve standards of care and outcomes for patients here.

Business • 11 Feb

Roche is buying Poseida for $9 a share in cash

Malin shares soar as Roche agrees to buy Poseida

Shares in Irish life sciences company Malin were up over 40% today after it announced US firm Poseida, in which it has invested, is to be sold.

Business • 26 Nov 24

Roche said the Swiss group could quickly offer 10 times more test kits for mpox than are currently in demand

Roche's third quarter sales beat market expectations

Drugs and diagnostic company Roche said its third-quarter sales gained a currency-adjusted 9%, beating market expectations, on higher prescriptions of once-monthly haemophilia shot Hemlibra and recently launched eye drug Vabysmo.

Business • 23 Oct 24

Roche said today that the rest of the year would no longer be burdened by year-earlier comparisons that were inflated by Covid-related sales

Roche's Q1 results hit by loss of Covid sales, forex

Roche has confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter sales slipped by 6% on the loss on Covid-19-related revenue.

Business • 24 Apr 24

Roche is forecasting a pick up in sales growth this year as it overcomes a slump in demand for its Covid-19 product

Roche overcomes drop in Covid sales

Roche has today forecast a pick up in sales growth this year as it overcomes a slump in demand for its Covid-19 products and a decline in sales of a trio of established cancer drugs abates.

Business • 01 Feb 24

Pre-tax profits at the Roche unit dipped despite revenues increasing by 11% cent from €105 million to €116.3 million

Ireland among slowest countries to re-imburse medicines

Patients here do not get the same speed of access to innovative and life changing medicines as their counterparts in other European countries.

Business • 20 Dec 23

Roche enters obesity drug market with Carmot deal

Roche has agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list of global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.

Business • 04 Dec 23

The WRC adjudicator also rejected an unfair dismissal complaint made by the complainant

Roche must pay whistleblower €8,000 compensation - WRC

Global pharma giant Roche has been ordered to pay a whistleblower €8,000 in compensation for penalising him after he made a protected disclosure to the State medicines regulator.

Business • 16 Nov 23

Roche has today announced a deal for Telavant Holdings, which has developed a new treatment for inflamatory bowel diseases

Roche buys Telavant Holdings for $7.1 billion

Roche said today it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from US biotech firm Roivant Holdings and Pfizer.

Business • 23 Oct 23

Roche said that market participants had made it aware of the inadvertent disclosure of an interim data analysis on new immunotherapy tiragolumab

Roche inadvertently publishes positive trial data

Roche inadvertently published positive lung cancer drug trial data from an interim analysis, boosting the Swiss drug maker's shares even though more data will be needed to confirm the treatment's efficacy.

Business • 23 Aug 23

The firm's only revenues last year was €1.07m generated from the sale of scrap metal from the decommissioning

Roche bill for Clare plant decommissioning hits €57m

The bill to Swiss pharma giant, Roche, for decommissioning and demolishing its County Clare plant and connected environmental costs now totals €57.27m for a three year period.

Business • 09 May 23

The complainant is alleging he was unfairly dismissed

Sacked drug safety manager accused of false allegations

A sacked drug safety manager at Roche has been accused of making "false" allegations about his former colleagues to the Workplace Relations Commission by lawyers for the international pharma giant.

Business • 24 Feb 23

Drug safety manager alleges 'cover-up' at Roche

A drug safety manager at international pharma giant Roche has alleged before the Workplace Relations Commission that there was widespread non-compliance in marketing materials distributed by its Irish arm – not in error, but "with a commercial purpose".

Business • 23 Feb 23

New accounts filed by Roche Products (Ireland) Ltd show that pre-tax profits fell by 31% to €4.77m in 2021

Roche warns drug pricing agreement will curtail revenue

A new drugs pricing agreement with the Department of Health and the HSE will further curtail revenue growth at the Irish arm of pharma giant Roche.

Business • 16 Jan 23

Roche said its third-quarter revenue slipped to 14.74 billion Swiss francs ($14.84 billion)

Roche sales decline more than expected

Roche's quarterly sales declined 6% as a slump in Covid-19 treatments and diagnostic testing outweighed gains from haemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus.

Business • 18 Oct 22

Roche first quarter sales up 10%, confirms 2022 outlook

Swiss drugmaker Roche's first quarter sales rose a better-than-expected 10% on strong US demand for rapid Covid-19 antigen tests and drugs including Ocrevus against multiple sclerosis as well as Hemlibra against haemophilia.

Business • 25 Apr 22

Roche is bracing itself for less demand for its Covid-19 medicines and tests

Roche sees slower 2022 sales growth

Swiss drugmaker Roche said that sales growth would slow this year as it braces for less demand for its Covid-19 medicines and tests, expecting immunity against the novel coronavirus to prevail in the population from about April.

Business • 03 Feb 22

Roche said it was seeing demand for Covid-19 tests and strength in the overall business due to newly launched diagnostics platforms and medicines

Roche ups outlook as Delta variant spurs test demand

Swiss drugmaker Roche has raised its 2021 sales forecast after posting an 8% rise in nine-month revenues, powered by demand for Covid-19 tests and strength in the overall business due to newly launched diagnostics platforms and medicines.

Business • 20 Oct 21

The pharma giant announced in 2016 that it was to close its plant at Clarecastle after it failed to secure a buyer for the site

Roche Ireland recorded pre-tax loss of €35.5m in 2020

Costs associated with the shutdown and decommissioning of Roche's only Irish manufacturing plant at Clarecastle in Co Clare contributed to pre-tax losses soaring to €35.5m at Roche Ireland last year.

Business • 18 Aug 21

The Swiss drugmaker benefited from demand for Covid-19 tests

Roche sales rebound as Covid-19 tests help power growth

Roche's first-half net profit rose 2% to 8.22 billion Swiss francs ($8.96 billion) and sales increased by 8% at constant exchange rates to a better-than expected 30.71 billion francs as the Swiss drugmaker benefited from demand for Covid-19 tests.

Business • 22 Jul 21

Q1 sales of Covid-19 tests offset a slumping main drug business at Roche

Covid tests offset falling drugs sales at Roche

Swiss drugmaker Roche is sticking to its 2021 forecast for revenue growth, as first-quarter sales of Covid-19 tests offset a slumping main drug business that has been hurt as the pandemic limits doctor visits for other diseases.

Business • 21 Apr 21